Hyperhidrosis

Brickell Biotech Announces Proposed Underwritten Public Offering of Common Stock

Retrieved on: 
Wednesday, October 27, 2021
Research, Oppenheimer, William Blair & Company, SEC filing, Hyperhidrosis, Security (finance), U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, Policy, SEC, Leadership, Humanitarian use licenses, Time, Company, COVID-19, Attention, Nasdaq, BBI, Prospectus, Therapy, Autoimmunity, Intellectual property, GLOBE, Sale, Form, Pharmaceutical industry

BOULDER, Colo., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (Brickell), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases, announced today that it has commenced a proposed underwritten public offering of shares of its common stock.

Key Points: 
  • BOULDER, Colo., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (Brickell), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases, announced today that it has commenced a proposed underwritten public offering of shares of its common stock.
  • In connection with this offering, Brickell expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock at the public offering price, less the underwriting discount.
  • Brickell intends to use the net proceeds of this offering for research and development, including clinical trials, working capital, business development and general corporate purposes.
  • The forward-looking statements represent the estimates of Brickell as of the date hereof only, and Brickell specifically disclaims any duty or obligation to update forward-looking statements.

Brickell Biotech Announces Positive Topline Results, Achieving Statistical Significance on all Primary and Secondary Endpoints, from Both U.S. Phase 3 Pivotal Clinical Studies of Sofpironium Bromide Gel, 15% in Primary Axillary Hyperhidrosis Patients

Retrieved on: 
Thursday, October 7, 2021
Intellectual property, Incidence, Headache, Cardigan, Nervous system, Autoimmunity, University of Florida, Hyperhidrosis, Conference, COVID-19, Graduate, Constipation, Duane syndrome, Blood, Time, Webcast, Urinary retention, Sweatpants, Population, SEC, Humanitarian use licenses, Anticholinergic, Xerostomia, Șaeș, Prevalence, Common, Nature, University, Acetylcholine, II, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Policy, Exocrine gland, Research, Therapy, Mydriasis, Leadership, Patient, Medical device, Pharmaceutical industry

BOULDER, Colo., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases, today announced positive topline results from the Phase 3 pivotal Cardigan I and Cardigan II studies, which evaluated sofpironium bromide gel, 15% as a once daily topical formulation in patients with primary axillary hyperhidrosis (excessive underarm sweating).

Key Points: 
  • Overall, 89% of patients who were randomized to sofpironium gel, 15% in the studies completed the full six weeks of treatment.
  • Five (2.9%) and nine (5.0%) subjects who received sofpironium bromide gel, 15%, discontinued the Cardigan I and II studies, respectively, due to a TEAE.
  • The dial-in number for the conference call is 1-877-705-6003 for domestic participants and 1-201-493-6725 for international participants, with Conference ID #13723931.
  • A live webcast of the conference call can be accessed here or through the Investors tab on the Brickell Biotech website at https://www.brickellbio.com .

NovaBay Pharmaceuticals Signs Agreement to Acquire DERMAdoctor

Retrieved on: 
Tuesday, September 28, 2021
Cosmetics, Retail, Health, Other Retail, Pharmaceutical, Optical, Biotechnology, Hyperhidrosis, Goal, Rosacea, Earnout, QVC, Security (finance), Private Securities Litigation Reform Act, Ageing, U.S. Securities and Exchange Commission, Wound healing, Dermatitis, Marketing, Skin, Acquisition, Acne, LLC, KP duty, NovaBay Pharmaceuticals, Growth, Leadership, Science, Technology, Infection, Intellectual property, Keratosis pilaris, NYSE, Industry, Cosmetics, NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®, DERMAdoctor, NOVABAY PHARMACEUTICALS, INC.: GOING BEYOND ANTIBIOTICS®, DERMADOCTOR

DERMAdoctor produces and sells more than 30 products under lines that include Aint Misbehavin, Calm Cool + Corrected, Kakadu C, KP Duty, and Wrinkle Revenge.

Key Points: 
  • DERMAdoctor produces and sells more than 30 products under lines that include Aint Misbehavin, Calm Cool + Corrected, Kakadu C, KP Duty, and Wrinkle Revenge.
  • The DERMAdoctor skincare products have been clinically formulated to be highly effective yet gentle on skin, characteristics of our own CelleRx Clinical Reset.
  • In addition, Dr. Audrey Kunin is expected to join the NovaBay board of directors after the closing of the transaction.
  • NovaBay plans for the DERMAdoctor business to continue its operations from its current headquarters in Riverside, Missouri.

Brickell Biotech to Host Key Opinion Leader Webinar on DYRK1A and its Role in Autoimmunity

Retrieved on: 
Friday, September 17, 2021
Precision medicine, Massachusetts, Autoimmunity, Hyperhidrosis, Intellectual property, Inflammation, Virginia Mason Medical Center, Humanitarian use licenses, KOL, Benaroya Research Institute, Investor, Massachusetts Institute of Technology, DYRK1A, Patient, Down syndrome, Nasdaq, Technology, Clinical trial, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Harvard Medical School, Assistant, Hospital, Therapy, Transfusion medicine, Rheumatoid arthritis, Washington University in St. Louis, Clinical pathology, COVID-19, Dual, Degenerative disease, EDT, GLOBE, Massachusetts General Hospital, Atopic dermatitis, SEC, Research, Time, BBI, Leadership, Pharmaceutical industry

Brickells management team will also provide a brief update on the Companys investigational DYRK1A inhibitor platform.

Key Points: 
  • Brickells management team will also provide a brief update on the Companys investigational DYRK1A inhibitor platform.
  • The webinar will be accessible via a webcast posted on the Events and Presentation page in the Investors section of Brickells website at https://ir.brickellbio.com/events-presentations .
  • For those unable to watch this broadcasted event live, a replay will be available on the Brickell website following the event.
  • The forward-looking statements represent the estimates of Brickell as of the date hereof only, and Brickell specifically disclaims any duty or obligation to update forward-looking statements.

Botox and Fillers by Curated Medical: Why Clients Sign Up for Botox Injections at this Trusted Medical Spa

Retrieved on: 
Tuesday, September 14, 2021
Man, Hyperhidrosis, Professional, PDO, Nerve, Skin, Gonzaga University, DNP, Exocrine gland, Brain, Migraine, Pain, GLOBE, Mark (given name), Katie, Time, Woman, Perspiration, Birth control, Pharmaceutical industry

But Curated Medical offers treatments that stand out from the rest with its professionalism, safety measures and experience.

Key Points: 
  • But Curated Medical offers treatments that stand out from the rest with its professionalism, safety measures and experience.
  • Based in Scottsdale, Arizona, Botox and Fillers by Curated Medical offers Botox injections and much more for its clients.
  • Most people have heard of Botox injections , but not many know of the many benefits this amazing treatment can have for clients.
  • So, if youre searching for Botox Scottsdale and need a reliable, skilled aesthetic nurse practitioner, look no further than Curated Medical!

Axillary Hyperhidrosis (Dermatology) Drugs In Development, 2021 Report - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 9, 2021
Health, Pharmaceutical

Jun 29, 2021: Brickell Biotech announces final patient completed in first U.S. phase 3 pivotal clinical study and patient enrollment completed in second U.S. phase 3 pivotal clinical study of Sofpironium Bromide Gel, 15% for the treatment of primary axillary hyperhidrosis

Key Points: 
  • Jun 29, 2021: Brickell Biotech announces final patient completed in first U.S. phase 3 pivotal clinical study and patient enrollment completed in second U.S. phase 3 pivotal clinical study of Sofpironium Bromide Gel, 15% for the treatment of primary axillary hyperhidrosis
    Jun 24, 2021: Brickell Biotech announces initiation of a phase 1 study of Sofpironium Bromide Gel in primary palmoplantar hyperhidrosis patients by its development partner, Kaken Pharmaceutical in Japan
    Jun 01, 2021: Brickell Biotech announces publication of Japan phase 3 long-term safety and efficacy study results for Sofpironium Bromide Gel, 5% (ECCLOCK) in the Journal of Dermatology
    Apr 27, 2021: Brickell Biotech completes patient enrollment in U.S. phase 3 pivotal Cardigan I study of Sofpironium Bromide Gel, 15% for the treatment of primary axillary hyperhidrosis
    Apr 23, 2021: Brickell Biotech reports results from U.S. phase 3 open-label, long-term safety study on chronic use of sofpironium bromide gel as a potential treatment for primary axillary hyperhidrosis
    Jan 19, 2021: Brickell Biotech announces publication of Japan pivotal phase 3 study results for Sofpironium Bromide Gel, 5% (ECCLOCK) in the Journal of Dermatology
    Dec 07, 2020: Brickell Biotech doses first patient in second U.S. pivotal phase 3 clinical study
    Nov 18, 2020: Brickell Biotech announces launch date for sofpironium bromide gel, 5% (ECCLOCK) in Japan by its development partner, Kaken Pharmaceutical
    Oct 06, 2020: Brickell Biotech announces initiation of U.S. phase 3 program evaluating sofpironium bromide gel, 15% for the treatment of Primary Axillary Hyperhidrosis
    Sep 25, 2020: Brickell Biotech announces approval of sofpironium bromide gel, 5% in Japan for treatment of primary axillary hyperhidrosis received by its development partner, Kaken Pharmaceutical
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005682/en/

RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021

Retrieved on: 
Tuesday, September 7, 2021

said Dr. Lynn Webster, Pain Researcher and Clinician and Senior Fellow at the Center of U.S. Policy.

Key Points: 
  • said Dr. Lynn Webster, Pain Researcher and Clinician and Senior Fellow at the Center of U.S. Policy.
  • "There has been a shift in clinical practice to try to reduce doses of opioids used to treat chronic pain.
  • Symptoms consistent with opioid withdrawal, including hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability, and yawning, occurred in patients treated with Movantik.
  • You are encouraged to report Adverse Reactions to RedHill Biopharma Inc. at1-833-ADRHILL(1-833-237-4455)or FDA at1-800-FDA-1088or www.fda.gov/medwatch .

RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021

Retrieved on: 
Tuesday, September 7, 2021

TEL AVIV, Israel and RALEIGH, N.C., Sept. 7, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced presentation at PAINWeek 2021 of three new analyses of Movantik® (naloxegol) Phase 3 study data demonstrating rapid onset of action and sustained and predictable improvement of key symptoms associated with opioid-induced constipation (OIC) in both a subgroup of patients aged ≥ 65 and across both low and high dose opioid therapy.

Key Points: 
  • said Dr. Lynn Webster, Pain Researcher and Clinician and Senior Fellow at the Center of U.S. Policy.
  • "There has been a shift in clinical practice to try to reduce doses of opioids used to treat chronic pain.
  • Symptoms consistent with opioid withdrawal, including hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability, and yawning, occurred in patients treated with Movantik.
  • You are encouraged to report Adverse Reactions to RedHill Biopharma Inc. at1-833-ADRHILL(1-833-237-4455)or FDA at1-800-FDA-1088or www.fda.gov/medwatch .

Beverly Wilshire Aesthetics Opens its Doors with an Expert Approach to Leading Edge Nonsurgical Cosmetic Procedures

Retrieved on: 
Friday, September 3, 2021
Well, Technology, Perspiration, Hyperpigmentation, Epidermis, Hyperhidrosis, Skin, Collagen, Titanium metallic discoloration, Rosacea, Acne, Muscle, Health, Beverly Wilshire Hotel, Dentistry, Cosmetics, Medical device

--- Juvederm and other facial fillers are also available. Dr. Zarrini says that these procedures are ideal when it comes to reducing wrinkling and plumping up lips and cheeks, as well as removing the appearance of sunken eyes.

Key Points: 
  • LOS ANGELES, Sept. 3, 2021 /PRNewswire-PRWeb/ -- Beverly Wilshire Aesthetics is now open and is offering a range of non-surgical cosmetic procedures to people from throughout the Greater Los Angeles area and beyond.
  • The spa offers a long list of innovative procedures including:
    --- Lumecca IPL , a treatment for many types of skin blemishes and discoloration, including hyperpigmentation, rosacea, and acne.
  • "Being a doctor also allows me to take a more holistic approach in terms of the interaction of health and appearance.
  • Beverly Hills Aesthetics is located at 9100 Wilshire Blvd #363 in Beverly Hills near Doheny Drive.

Brickell Biotech Acquires Exclusive Rights to Phase 1-Ready DYRK1A Inhibitor Program and Novel Platform Targeting Autoimmune and Inflammatory Diseases

Retrieved on: 
Wednesday, September 1, 2021
DYRK1A, Trial of the century, Rheumatoid arthritis, SEC, Leadership, Research, Hyperhidrosis, Intellectual property, Precision medicine, Partnership, Bangalore Bio-Cluster, University, Transfection, Therapy, U.S. Securities and Exchange Commission, Large-cell lung carcinoma, Doctor of Philosophy, BBI, Lead, T helper cell, Humanitarian use licenses, Time, Degenerative disease, Clinical trial, Conference, JAK, Technology, MD, Nasdaq, Inflammation, Assistant, Autoimmunity, Affiliation, Translational medicine, Cytokine, Dermatology, Drug development, Company, Atopic dermatitis, University of Washington Department of Bioengineering, Acquisition, GLOBE, Immune system, Private Securities Litigation Reform Act, RET, Patient, Benaroya Research Institute, COVID-19, Pharmaceutical industry

BOULDER, Colo., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases, today announced it has entered into a definitive agreement with Voronoi Inc., a platform-based drug discovery company in South Korea dedicated to developing new kinase inhibitors, that grants Brickell exclusive, worldwide rights to research, develop and commercialize novel therapeutics generated from a proprietary DYRK1A inhibitor platform. These novel DYRK1A inhibitors aim to restore immune balance in patients whose immune system has become dysregulated, thus offering large potential across a wide array of autoimmune and inflammatory diseases.

Key Points: 
  • These novel DYRK1A inhibitors aim to restore immune balance in patients whose immune system has become dysregulated, thus offering large potential across a wide array of autoimmune and inflammatory diseases.
  • Notably, many current therapies for autoimmune disorders are broadly immunosuppressant, which may lead to severe side effects, such as increased infection risk.
  • We are excited to announce the partnering of our novel DYRK1A inhibitor platform with Brickell, said Daekwon Kim, Chief Executive Officer of Voronoi.
  • Brickell will be responsible for all future development activities and expenses related to the DYRK1A inhibitor platform.